Guest editors' introduction: What can large pragmatic clinical trials do for public mental health care?

Schizophrenia Bulletin

Volumn 29, Issue 1, 2003, Pages 1-6

  Lieberman, Jeffrey A ^a   Stroup, T Scott ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL TRIAL; DECISION MAKING; DRUG INFORMATION; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MENTAL HEALTH CARE; PRIORITY JOURNAL;

EID: 0038487364     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a006979     Document Type: Editorial

References (16)

1. Abelson, R. Hard decisions for employers as costs soar in health care. New York Times, April 18(Section C):1, 2002.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288:2981-2997, 2002.
3. Berndt, E.R. The U.S. pharmaceutical industry: Why major growth in times of cost containment? Health Affairs, 20(2):100-114, 2001.
4. Chakos, M.; Lieberman, J.; Hoffman, E.; Bradford, D.; and Sheitman, B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. American Journal of Psychiatry, 158(4):518-526, 2001.
5. Freudenheim M. V.A. health care strained by big wave of enrollees. New York Times, April 6(Section A):1, 2002.
6. Geddes, J.; Freemantle, N.; Harrison, P.; and Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. British Journal of Medicine, 321:1371-1376, 2000.
7. Leucht, S.; Pitschel-Walz, G.; Abraham, D.; and Kissling, W. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials. Schizophrenia Research, 35(1):51-68, 1999.
8. Levit, K.; Smith, C.; Cowan, C.; Lazenby, H.; Sensinig, A.; and Catlin, A. Trends in U.S. health care spending, 2001. Health Affairs, 22(1):154-164, 2003.
9. Pear, R. After decline, the number of uninsured rose in 2001. New York Times, September 30(Section A):22, 2002a.
10. Pear, R. States are facing big fiscal crises, governors report. New York Times, November 26(Section A):14, 2002b.
11. Pear, R. Medicare to cut payments to doctors 4.4 percent next year. New York Times, December 21(Section A):1, 2002c.
12. Sartorius, N.; Fleischhacker, W.W.; Gjerris, A.; Kern, U.; Knapp, M.; Leonard, B.E.; Lieberman, J.A.; López-Ibor, J.J.; van Raay, B.; and Twomey, E. The usefulness and use of second-generation antipsychotic medications. Current Opinion in Psychiatry, 15(Suppl 1):S1-S51, 2002.
13. Strunk, B.C.; Ginsburg, P.B.; and Gabel, J.R. Tracking health care costs. Health Affairs (Suppl Web exclusives):W39-W50, 2001.
14. Tuunainen, A.; Wahlbeck, K.; and Gilbody, S. Newer atypical antipsychotic medication in comparison to clozapine: A systematic review of randomized trials. Schizophrenia Research, 56(1-2):1-10, 2002.
15. Wahlbeck, K.; Tuunainen, A.; Ahokas, A.; and Leucht, S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacologia, 155(3):220-223, 2001.
16. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA, 288:321-333, 2002.